Lataa...
Cabozantinib and apixaban: an hitherto unreported interaction
The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment with possible drug-drug interaction with other drugs such as oral anticoagulant. We descri...
Tallennettuna:
| Julkaisussa: | Exp Hematol Oncol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6737677/ https://ncbi.nlm.nih.gov/pubmed/31528502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0146-9 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|